Ascelia Pharma publishes Orviglance liver MRI contrast agent study in JMRI
Bitget2026/09/24 05:30- Ascelia Pharma announced publication of a peer-reviewed Orviglance clinical study in the Journal of Magnetic Resonance Imaging.
- Results were already presented via the journal article, not flagged for a future medical meeting.
- Study assessed a single oral dose in adults with hepatic impairment versus those without impairment.
- Publication supports Orviglance’s differentiated profile as a manganese-based liver MRI contrast agent, reinforcing its clinical development rationale.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analysis: Wall Street Is Not Yet Ready to Short AI in Large Numbers
Overseas capital is aggressively buying US stocks! Net inflows reached $942 billions over the past 12 months, marking a record since 1985.
According to data from the US Department of the Treasury, in the 12 months ending July this year, overseas investors made net purchases of US stocks totaling $942 billion, marking the highest rolling 12-month total since records began in 1985. The net purchases in the second quarter alone reached $426 billion, setting a new single-quarter record. Meanwhile, overseas demand for US Treasuries has noticeably cooled, with purchase volumes falling significantly. As a result, the US is facing higher costs in government debt financing.
RootData: BIO will unlock tokens worth about $1 million in one week
Crypto prices
More
